{"denoms":[{"counts":[{"groupId":"BG000","value":"942"},{"groupId":"BG001","value":"944"},{"groupId":"BG002","value":"1886"}],"units":"Participants"}],"groups":[{"description":"Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m\\^2 IV bolus injection + 5-FU 425 mg/m\\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m\\^2 by two-hour IV infusion + 5-FU 500 mg/m\\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)","id":"BG000","title":"5-FU/LV"},{"description":"Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)","id":"BG001","title":"XELOX"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.76","value":"60.5"},{"groupId":"BG001","spread":"10.95","value":"59.8"},{"groupId":"BG002","spread":"10.86","value":"60.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"442"},{"groupId":"BG001","value":"431"},{"groupId":"BG002","value":"873"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"500"},{"groupId":"BG001","value":"513"},{"groupId":"BG002","value":"1013"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"442"},{"groupId":"BG001","value":"431"},{"groupId":"BG002","value":"873"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"500"},{"groupId":"BG001","value":"513"},{"groupId":"BG002","value":"1013"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}